Endurance RP A New Perspective Eye on China's fertility and longevity market

24 June 2021 | Thursday | News

This rebranding strategy reflects both the evolution of the company as well as its vision towards the longevity, healthcare, wellness, and life sciences sectors for the future.
Image Source : Public Domain

Image Source : Public Domain

Endurance RP Limited ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK) is pleased to announce the official completion of the rebranding of the Group, with the Company name changed to "Endurance RP Limited" with effect from 18 June 2021. The stock short name of the Company for trading in the Shares on the HK Stock Exchange will be changed to "ENDURANCE RP" from "Regent Pacific" with effect from 9:00 a.m. on 28 June 2021. The stock code "575" remains unchanged, meanwhile, the Company has adopted a new company logo, and the website address will be changed to www.endurancerp.com with effect from 30 June 2021, signalling the Group's embarkation to proactively promote its wellness and longevity businesses.

Jamie Gibson, Chief Executive Officer of the Company, said, "We are excited to introduce our new company identity as it reflects the Group's business strategies, focus and market positioning, and its determination to make a statement in the future of the longevity business, as well as enhancing its corporate image and competitiveness, especially after the acquisition of Deep Longevity, a company developing artificial intelligence to track human aging and extend productive longevity. The acquisition of Deep Longevity injected state-of-the-art aging clock technologies and exceptional brand value into the Group. With a burgeoning number of elderlies and increasing focus on geroprotection, extending human life and improving performance are of utmost important, which will create huge business opportunity for the longevity industry."

Jamie added, "In addition, Fortacin™, our core treatment for PE is expected to benefit with the introduction of mainland China's Three Child Policy in May 2021. It is estimated that Fortacin™ will be launched in mainland China in 2023 and has the potential to help an initial target market of approximately 9 million patients in mainland China in its first year of launch."

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in